Novartis sees brighter sales future as R&D revamp continues

The pharma has overhauled its pipeline this year, cutting R&D programs outside of its four main therapeutic areas.

By Ned Pagliarulo • Nov. 28, 2023

Pharma benefited from basing business overseas. An international tax effort could spur a rethink.

U.S. tax law changes six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.

By Jonathan Gardner • Nov. 28, 2023

Explore the Trendline➔

COVID-19 vaccines

The urgency of the pandemic’s first two years is giving way to questions of how to sustain public health responses and prepare for what could come next. In the U.S., health officials are urging booster shots and preparing for private sector distribution of vaccines.

By BioPharma Dive staff

Novo to expand French plant in GLP-1 production push

The planned $2.3 billion investment follows an earlier $6 billion commitment to expand manufacturing for drugs like its in-demand medicine Wegovy.

By Delilah Alvarado • Nov. 27, 2023

Merck to buy private biotech Caraway in neuroscience deal

In a deal worth up to $610 million, Merck will gain a pipeline of neuroscience and rare disease programs from a startup it previously backed.

By Delilah Alvarado • Nov. 21, 2023

Bayer ends large blood thinner trial for ‘inferior efficacy’

Company shares fell after study monitors called for halting a planned 18,000-person trial because Bayer’s drug wasn’t working as well as Eliquis.

By Jonathan Gardner • Updated Nov. 20, 2023

Bristol Myers faces FDA delay on cancer cell therapy decision

The regulator plans to convene an advisory panel to discuss an expanded indication for Abecma, presenting another hurdle for Bristol Myers and partner 2seventy bio.

By Ned Pagliarulo • Nov. 20, 2023

AstraZeneca creates digital health unit, with big-name partnerships already in place

Called Evinova, the unit will operate as a separate business within AstraZeneca, which sees digital health solutions as a market primed for growth.

By Jacob Bell • Nov. 20, 2023

Lilly plans new $2.5B manufacturing plant as obesity drug demand ramps up

Following the approval of Zepbound, Lilly is adding capacity to avert shortages and restricted access.

By Jonathan Gardner • Nov. 17, 2023

Paper details Astellas gene therapy study that led to patient deaths

The company, which is working with regulators to lift a clinical hold, said the treatment could still help people with X-linked myotubular myopathy.

By Kristin Jensen • Nov. 16, 2023

FDA approves new Bristol Myers drug for lung cancer

Acquired via a $4 billion biotech buyout, Augtyro is one of an array of new products the pharma hopes will offset patent expirations for current top sellers.

By Jonathan Gardner • Nov. 16, 2023

3 ways decentralized clinical trials could help advance research on rare diseases

Explore how decentralized clinical trials (DCTs) can enhance rare disease research in three key ways.

Nov. 13, 2023

Detailed trial data confirm Wegovy heart benefit

As GLP-1 drugs for weight loss take off, the results for Novo Nordisk’s treatment could help convince insurers to expand coverage.

By Jonathan Gardner • Nov. 11, 2023

AstraZeneca stays in GLP-1 drug race with new deal

AstraZeneca is paying $185 million upfront to gain access to an experimental GLP-1 drug from China-based biotech Eccogene.

By Jonathan Gardner • Nov. 9, 2023

Bayer’s new CEO signals business shake-up, plans to slash management

Company head Bill Anderson said Bayer may separate its consumer health or crop science business, and signaled “significant” layoffs are in the future.

By Kristin Jensen • Nov. 8, 2023

Moderna adjusts to changing outlook for COVID vaccine demand

The company recorded a net loss in the third quarter as it “resizes” its manufacturing footprint, and now expects revenue to come in at low end of its previous guidance.

By Delilah Alvarado • Nov. 3, 2023

Novo, Lilly buoyed by fast-growing GLP-1 drug sales

The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.

By Jonathan Gardner • Nov. 2, 2023

Pfizer RSV vaccine gets off to fast start on market

The pharma’s shot Abrysvo made over $300 million in sales during the first few months of its launch, and will be an important product to help offset declining COVID-19 vaccine sales.

By Delilah Alvarado • Oct. 31, 2023

Novartis bet on kidney disease drug yields positive study data

The pharma paid more than $3 billion this summer to acquire Chinook Therapeutics and a therapy that just met its goal in a Phase 3 trial.

By Ned Pagliarulo • Oct. 30, 2023

Why prospective real-world studies hold so much promise for clinical research

PrwS studies can reach beyond the limitations of today’s RWE studies and expand the role of RWD across the entire drug development cycle.

By Josh Buddle, Director of Clinical Operations, Flatiron Health • Oct. 30, 2023

Bristol Myers’ neuroscience research head explains the big pharma’s return to brain drugs

Bristol Myers’ Ken Rhodes spoke with BioPharma Dive about biomarkers, diseases of interest and why the company is far from done with neuroscience-focused deals.

By Jacob Bell , Ned Pagliarulo • Oct. 27, 2023

Sanofi to divest consumer unit, joining pharma industry shift

The restructuring came as the French company forecast an earnings drop in 2024, prompting a stock selloff that erased about $20 billion in market value.

By Jonathan Gardner • Oct. 27, 2023

Bristol Myers says new drugs sales will grow more slowly

Company shares fell Thursday as the company adjusted its medium-term guidance for sales of new products like Reblozyl, Camzyos and Abecma.

By Ned Pagliarulo • Oct. 26, 2023

Amgen to lay off 350 Horizon staffers weeks after closing $28B deal

The latest round of cuts brings the company’s total announced workforce reductions this year to more than 1,000.

By Kristin Jensen • Oct. 25, 2023

Novartis delays FDA filing for in-demand radiopharma drug

Mixed survival data from a study of Pluvicto in earlier prostate cancer sparked the slower regulatory timeline.

By Jonathan Gardner • Oct. 24, 2023

J&J medtech head Ashley McEvoy to step down

McEvoy is leaving the company after 27 years to pursue other opportunities. Tim Schmid will now lead the MedTech business.

By Elise Reuter • Updated Oct. 24, 2023